Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT03444506 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG: Molo 1 (also referred as GSP 301-2 NS)
DRUG: Molo 2 (also referred as GSP 301-1 NS)
DRUG: Placebo nasal spray
DRUG: DYMISTA nasal spray
DRUG: PATANASE nasal spray

Sponsor

Glenmark Pharmaceuticals Ltd. India